IIM
NBIX icon

INTECH Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

INTECH Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7M Sell
63,662
-22,653
-26% -$3.36M 0.1% 179
2026
Q1 		$11.4M Buy
86,315
+45,837
+113% +$6.08M 0.11% 157
2025
Q4 		$5.74M Buy
40,478
+5,823
+17% +$844K 0.05% 324
2025
Q3 		$4.86M Buy
34,655
+6,307
+22% +$855K 0.04% 387
2025
Q2 		$3.56M Sell
28,348
-7,476
-21% -$857K 0.03% 470
2025
Q1 		$3.96M Sell
35,824
-82,590
-70% -$10.5M 0.04% 405
2024
Q4 		$16.2M Buy
118,414
+15,819
+15% +$1.96M 0.16% 97
2024
Q3 		$11.8M Buy
102,595
+33,897
+49% +$4.65M 0.13% 144
2024
Q2 		$9.46M Buy
68,698
+44,512
+184% +$6.1M 0.12% 158
2024
Q1 		$3.34M Buy
24,186
+11,921
+97% +$1.63M 0.05% 289
2023
Q4 		$1.62M Sell
12,265
-5,328
-30% -$613K 0.02% 365
2023
Q3 		$1.98M Sell
17,593
-3,088
-15% -$325K 0.03% 351
2023
Q2 		$1.95M Buy
20,681
+16,398
+383% +$1.6M 0.02% 376
2023
Q1 		$434K Sell
4,283
-303
-7% -$31.5K ﹤0.01% 628
2022
Q4 		$548K Buy
4,586
+303
+7% +$35.5K ﹤0.01% 594
2022
Q3 		$455K Buy
4,283
+307
+8% +$31.1K ﹤0.01% 602
2022
Q2 		$388K Buy
+3,976
New +$367K ﹤0.01% 628

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

INTECH Investment Management's NBIX Position: Q2 2026 in Review

INTECH Investment Management reduced its Neurocrine Biosciences (NBIX) stake by 26% in Q2 2026, selling an estimated $3.36M and leaving 63,662 shares worth $10.7M. The position accounts for 0.1% of the portfolio, ranked #179.

INTECH Investment Management first reported a position in NBIX in Q2 2022 and has held it in 17 quarters since. The position peaked at $16.2M in Q4 2024. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • INTECH Investment Management held 63,662 shares of Neurocrine Biosciences worth $10.7M as of Q2 2026.
  • INTECH Investment Management sold 22,653 Neurocrine Biosciences shares in Q2 2026, an estimated $3.36M.
  • Neurocrine Biosciences made up 0.1% of INTECH Investment Management's portfolio in Q2 2026, its #179 holding.
  • INTECH Investment Management first reported a position in Neurocrine Biosciences in Q2 2022 and has held it in 17 quarters since.
  • INTECH Investment Management's Neurocrine Biosciences position peaked at $16.2M in Q4 2024.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.